Anzeige
Meldung des Tages: Gold im Fokus: Warum diese milliardenschwere Goldaktie vom aktuellen Goldumfeld profitieren könnte

OKYO PHARMA LTD News

Aktie
WKN:  A2JQ3D ISIN:  GG00BD3FV870 US-Symbol:  EMMLF
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
68,08%
KGV
-
Index-Zuordnung
-

OKYO PHARMA LTD News

10.03.25 - GlobeNewswire
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
LONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-​stage biopharmaceutical company developing innovative ...
12.02.25 - GlobeNewswire
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
31.01.25 - GlobeNewswire
OKYO Pharma Announces Chairman and CEO Acquire Shares
LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
29.01.25 - GlobeNewswire
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
22.01.25 - GlobeNewswire
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
26.11.24 - GlobeNewswire
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference
LONDON and NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
30.10.24 - GlobeNewswire
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
23.10.24 - GlobeNewswire
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial The Phase 2 trial is designed as a randomized, ...
16.10.24 - GlobeNewswire
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan disease OKYO is the first company to have an IND application ...
10.09.24 - GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
05.09.24 - GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
LONDON and NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
27.08.24 - GlobeNewswire
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
23.08.24 - GlobeNewswire
OKYO Pharma CEO Interview to Air on Bloomberg TV
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
23.08.24 - GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
21.08.24 - GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
15.08.24 - GlobeNewswire
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
06.08.24 - GlobeNewswire
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
11.07.24 - GlobeNewswire
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
Phase 2 randomized, placebo-​controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by ...
10.07.24 - GlobeNewswire
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient ...
08.05.24 - GlobeNewswire
OKYO Pharma Announces Participation in May 2024 Investor Conferences
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...

Newssuche

Videos

newspaper
10:20 Uhr +6,70%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »